Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABVD DD-DI versus interim PET-adapted ABVD in advanced classical Hodgkin lymphoma
2016-002509-21Phase 3Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Jun 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of doxorubicin, bleomycin, vinblastine and dacarbazine in classical Hodgkin lymphoma (cHL) (2 arms), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Progression-free survival. Started Jun 2021; status: completed.
02
Drugs
doxorubicinbleomycinvinblastinedacarbazine
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2016-002509-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002509-21.